EGFR and EML4-ALK gene mutations in NSCLC: A case report of erlotinib-resistant patient with both concomitant mutations

M. Tiseo, F. Gelsomino, D. Boggiani, B. Bortesi, M. Bartolotti, C. Bozzetti, G. Sammarelli, E. Thai, A. Ardizzoni

Research output: Contribution to journalArticlepeer-review

Abstract

The fusion gene EML4-ALK (echinoderm microtubule-associated protein-like 4 gene and the anaplastic lymphoma kinase gene) was recently identified as a novel genetic alteration in non-small cell lung cancer (NSCLC). EML4-ALK translocations correlate with specific clinical and pathological features, in particular lack of EGFR and K-ras mutations, and may be associated with resistance to EGFR tyrosine-kinase inhibitors (TKIs). Here, we report a case of a patient with a concomitant EGFR mutation and ALK translocation resistant to erlotinib. Considering this report, ALK status should be investigated in unexplained cases of EGFR-TKI-resistance of EGFR mutated NSCLCs.

Original languageEnglish
Pages (from-to)241-243
Number of pages3
JournalLung Cancer
Volume71
Issue number2
DOIs
Publication statusPublished - Feb 2011

Keywords

  • EGFR mutations
  • EML4-ALK
  • Erlotinib
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint

Dive into the research topics of 'EGFR and EML4-ALK gene mutations in NSCLC: A case report of erlotinib-resistant patient with both concomitant mutations'. Together they form a unique fingerprint.

Cite this